- Non-invasive imaging technique called 31-phosphorus magnetic resonance spectroscopy used to measure mitochondrial function in patients with motor neuron disease (MND)
- Evidence shows that mitochondria - often referred to as the cell's battery - are impaired in MND
- This technique could be used to measure the effectiveness of future treatments for MND
Researchers from the Sheffield Institute for Translational Neuroscience (SITraN) have used a new imaging technique to measure the function of mitochondria in patients with motor neuron disease (MND).
The research, published today (13 January 2021) in the journal Brain could provide new ways to assess the effectiveness of treatments currently in development for MND.
Researchers used an advanced imaging technique called 31-phosphorus magnetic resonance spectroscopy to measure chemicals that are crucial to energy metabolism in the cell. The research was conducted on patients living with MND as well as age and gender matched healthy controls. The patient perceives the procedure as a standard MRI scan but researchers are able to gain a direct measurement of chemicals so that they can calculate a comprehensive picture of the energy status in patients with MND.
MND, or amyotrophic lateral sclerosis (ALS), as it is also known, is a disorder that affects the nerves - motor neurons - in the brain and spinal cord that form the connection between the nervous system and muscles to enable movement of the body. The messages from these nerves gradually stop reaching the muscles, leading them to weaken, stiffen and waste.
There are many barriers to developing effective treatments for MND as we don't yet fully understand how or why it develops in the first place. However, there is good evidence from laboratory data and disease models that the mitochondria - or powerhouses of the cell - may be impaired.
Lead author on the study, Dr Matilde Sassani from the University of Sheffield, explains: "It is important to have an effective technique to measure mitochondrial function in vivo in patients living with MND.
"In this study we found that phosphocreatine levels were depleted in the brain compared to healthy controls and, in the muscle, we found that inorganic phosphates were elevated in patients with MND. Both of these findings are consistent with mitochondrial dysfunction occurring in these people living with MND."
Dr Thomas Jenkins, senior author of the paper and Clinical Senior Lecturer at SITraN, said: "This research has the potential to impact the development of more effective treatments for MND. It appears to be a promising tool with potential to measure the effect of medications acting on mitochondrial function in people living with MND.
"Treatments that aim to rescue mitochondrial function in MND are being investigated in labs around the world. This non-invasive tool can demonstrate whether medications in development are successfully targeting mitochondria, which is an important step in selecting treatments to take through to clinical trials."
Future research aims to widen the scope of this study to include larger numbers of MND patients. As the mitochondria are also thought to be a factor in a range of other neurodegenerative diseases, there may be potential for this technique to be widened to different patient groups.
###
The study was supported by charitable funding from Neurocare, the Ryder Briggs Trust and a British Medical Association Vera Down grant, and by the NIHR Sheffield Biomedical Research Centre.
The research is part of the Neuroscience Institute at the University of Sheffield which brings together leading experts in medicine, science and engineering to better understand the nervous system and tackle the biggest challenges in neuroscience.
Media contact:
Amy Huxtable,
Media Relations Officer,
University of Sheffield,
0114 222 9859,
a.l.huxtable@sheffield.ac.uk
Notes to editors:
The University of Sheffield
With almost 29,000 of the brightest students from over 140 countries, learning alongside over 1,200 of the best academics from across the globe, the University of Sheffield is one of the world's leading universities.
A member of the UK's prestigious Russell Group of leading research-led institutions, Sheffield offers world-class teaching and research excellence across a wide range of disciplines.
Unified by the power of discovery and understanding, staff and students at the university are committed to finding new ways to transform the world we live in.
Sheffield is the only university to feature in The Sunday Times 100 Best Not-For-Profit Organisations to Work For 2018 and for the last eight years has been ranked in the top five UK universities for Student Satisfaction by Times Higher Education.
??Sheffield has six Nobel Prize winners among former staff and students and its alumni go on to hold positions of great responsibility and influence all over the world, making significant contributions in their chosen fields.
Global research partners and clients include Boeing, Rolls-Royce, Unilever, AstraZeneca, Glaxo SmithKline, Siemens and Airbus, as well as many UK and overseas government agencies and charitable foundations.
Journal
Brain